Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Amgen's AMG 145 Lowers Bad Cholesterol Levels

RELATED NEWS
Trade AMGN now with 

Amgen Inc. (AMGN: Quote) Monday said its experimental drug AMG 145 in combination with statin therapy reduced bad cholesterol levels in patients.

AMG 145 is an investigational antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol (LDL-C) or bad cholesterol from the blood.

Amgen in a statement said AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in LDL-C by up to 56 percent in patients with heterozygous familial hypercholesterolemia (HeFH) in the Phase 2 Rutherford study.

HeFH, one of the most common genetic disorder, elevates the cholesterol and LDL-C levels and leads to cardiovascular diseases and death.

The company said treatment with AMG 145 every four weeks resulted in a significant LDL-C decrease versus placebo in HeFH patients on lipid-lowering therapy.

At week 12, LDL-C reduction was 43 percent and 55 percent with AMG 145 350 mg and 420 mg, respectively, compared to a 1 percent increase with placebo arm.

"Despite existing therapies and maintaining a healthy lifestyle, patients with heterozygous familial hypercholesterolemia are prematurely at risk for serious cardiovascular disease due to the difficulty in reducing their LDL-C levels," said Frederick Raal, Carbohydrate & Lipid Metabolism Research Unit, Division of Endocrinology & Metabolism, Department of Medicine, University of the Witwatersrand, Johannesburg.

Register
To receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Bundesbank President Jens Weidmann has criticized the European Central Bank's latest measures to boost the euro area economy, such as the planned purchases of covered bonds and asset-backed securities and covered bonds, as well as the interest rate reduction this month. The latest decisions suggest... European stocks are seen opening lower on Monday, tracking weak commodity prices and a subdued trend across the Asia-Pacific region as investors look ahead to Chinese manufacturing data due on Tuesday for important clues about China's growth outlook. China is experiencing stable growth and there... Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.